Accuvest Global Advisors Eli Lilly & CO Transaction History

Accuvest Global Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$592.2 - $792.28 $88,830 - $118,842	-150 Reduced 3.85%	3,750 $2.92 Million
Q4 2023 Feb 13, 2024	SELL	$525.19 - $619.13 $8,403 - $9,906	-16 Reduced 0.41%	3,900 $2.27 Million
Q3 2023 Nov 13, 2023	SELL	$434.7 - $599.3 $210,394 - $290,061	-484 Reduced 11.0%	3,916 $2.1 Million
Q2 2023 Aug 11, 2023	SELL	$350.74 - $468.98 $420,888 - $562,776	-1,200 Reduced 21.43%	4,400 $2.06 Million
Q1 2023 May 12, 2023	BUY	$310.63 - $364.82 $1.74 Million - $2.04 Million	5,600 New	5,600 $1.92 Million
Q2 2022 Aug 12, 2022	BUY	$278.73 - $327.27 $197,340 - $231,707	708 New	708 $230,000

3,887

763M

6.34M

7.97M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $864B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Accuvest Global Advisors, based on Form 13F filings with the SEC.

Stay updated on Accuvest Global Advisors with notifications on news.